2020, with the sudden and severe emergence of SARS-CoV-2, has shown that teaming-up and collaborating is our best option in coming together against a pandemic. More than ever, BIOASTER’s purpose...
BIOASTER, Université de Technologie de Compiègne, Hospices Civils de Lyon and bioMérieux formalize strategic collaboration to conduct Next Generation Sequencing technology evaluation in microbiology Lyon, December 2, 2020 – BIOASTER...
Register to the 4th edition of Immunotherapies & Innovations for Infectious Diseases congress! December 9th & 10th, 2020. This year the conference will be held only in digital and will...
Open Call: Apply for TRANSVAC2 Vaccine Development Services Developing a vaccine is a time-consuming and complex process, requiring a combination of specialized skills and technical capacities not readily available at...
PRE-PRINT COVID19: Discovery of clinically approved drugs capable of inhibiting SARS-CoV-2 in vitro infection using a phenotypic screening strategy and network-analysis to predict their potential to treat covid-19 Authors: Douglas...
BIOASTER first shareholder with its two co-founders Adama OUATTARA and Wassim ABOU-JAOUDE of Gencovery. Wishing success to the first BIOASTER start-up. Gencovery provides cutting-edge software based on digital organisms for...
“Caecal microbiota compositions from 7-day-old chicks reared in high-performance and low-performance industrial farms and systematic culturomics to select strains with anti-Campylobacter activity”. See the article This work carried out in...
A droplet #microfluidics technology has been developed to measure #proteinsecretion kinetics from #singlecells. This technology has been successfully used to characterize monocyte anergy in septic shock patients. SharedIt link
BIOASTER welcomes the renewal of the support of the French Government. The Government thus strongly and clearly expresses its confidence in IRTs to develop and boost French technological research. This...
BIOASTER has entered into a collaboration agreement with Takeda to develop and validate new microbiome-based approaches in the context of Takeda’s clinical-stage assets for the treatment of gastrointestinal diseases. This...
Through this collaboration, BIOASTER and MaaT Pharma illustrate once again the dynamism and quality of the French ecosystem in the promising field of microbiome, as well as the success of...
By continuing browsing this website, you accept the use of cookies or other tracers for statistics of visits to optimize the functionality of the site, and or privacy policy. AcceptRejectRead More
Privacy & Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
